Anti-Pain Drugs Licensed To Lilly Boost Glenmark Earnings

NEW DELHI - Glenmark Pharmaceuticals said it expects further earnings gains from a portfolio of anti-pain drugs licensed to Eli Lilly and from products in its pipeline as it reorganizes its business into specialty and generic units